Le Lézard
Classified in: Health

Synergistic Therapeutics Announces It Has Obtained a US Patent for Its Topical Hair Loss Solution, Cresere


NAPLES, Fla., June 24, 2019 /PRNewswire/ -- Synergistic Therapeutics LLC has recently announced issuance of a U.S. Patent for a topical solution that slows hair loss and generates new hair growth in men and women(1,2). Synergistic Therapeutics LLC, a Florida-based company formed in 2015, specializes in manufacturing and formulating topical and sublingual pharmaceutical solutions. Cresere is a topical pharmaceutical composition with unique properties and multiple components that suppress inflammation while increasing blood flow, allowing high scalp penetration with no irritation(3). Cresere's formulation is made with finasteride and other proprietary compounds, which promotes hair growth and slows hair loss in a significantly higher percentage of patients than existing OTC and single compound products(4).

The American Hair Loss Association states that: "According to The Washington Post, American hair loss sufferers spend more than 3.5 billion dollars a year in an attempt to treat their hair loss(5)." In addition, "The vast majority of currently available hair loss treatments boast exaggerated claims, and most have absolutely no scientific backing whatsoever(6)." Cresere, with its patented prescription formula of finasteride and other proprietary compounds, has shown dramatic scientific results(7).

In addition to the hair loss solution, Synergistic Therapeutics maintains and holds patents for a topical analgesic and a sublingual anti-depression lozenge. The company also has products treating female sexual dysfunction and neuropathic pain. Contact the company via email at [email protected] for more information and inquiries.

Source (1)

https://jamanetwork.com/journals/jamadermatology/fullarticle/403800

Source (2)

https://www.goodrx.com/blog/finasteride-works-for-hair-loss-in-women/

Source (3)

https://www.ncbi.nlm.nih.gov/pubmed/29972712

Source (4)

https://www.ncbi.nlm.nih.gov/pubmed/29972712

Source (5)

https://www.americanhairloss.org/hair_loss_treatment/ 

Source (6)

https://www.reviews.com/hair-loss-treatment/

Source (7)

https://www.ncbi.nlm.nih.gov/pubmed/29972712

SOURCE Synergistic Therapeutics


These press releases may also interest you

at 03:38
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global...

at 03:35
The Japan Prize Foundation (President: Hiroshi Komiyama) held an award ceremony on Tuesday, April 16 at the Imperial Hotel Tokyo in Tokyo's Chiyoda Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the...

at 03:30
AMSilk GmbH ("AMSilk"), a global leader in advanced materials made from spider silk-based proteins, today announces the appointments of Ralph Fraundorfer and Ctibor Kohutovic to its Management Board starting immediately. Ralph Fraundorfer has been...

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...

at 02:24
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ('SciBase' or the 'Company') rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue'). The Rights Issue was resolved by the Board of...



News published on and distributed by: